Ionis Pharmaceuticals IONS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborative Agreement Revenue | $120.66M+130% | $52.4M+66.7% | $31.44M-90.7% | $336.92M+648% | $45.03M-53.5% | |
| Commercial | $107.81M-23.7% | $141.33M+22.3% | $115.6M+12.5% | $102.76M+34.9% | $76.17M-11.1% | |
| DAWNZERA Sales | $15.86M— | —— | —— | —— | $0— | |
| Other Commercial | $6.53M-14.6% | $7.65M-5.8% | $8.11M-40.0% | $13.53M+137% | $5.72M-32.3% | |
| Other Royalties | $3.9M-31.5% | $5.7M-12.0% | $6.48M+24.6% | $5.2M-23.3% | $6.78M+85.5% | |
| Research And Development Revenue | $138.28M+123% | $62.01M+50.8% | $41.12M-88.2% | $349.29M+530% | $55.44M-60.6% | |
| Royalty | $58.32M-23.0% | $75.72M0.0% | $75.69M+8.2% | $69.95M+9.0% | $64.17M-17.0% | |
| Spinraza Royalties | $43.71M-19.1% | $54.04M-3.3% | $55.9M+2.9% | $54.34M+13.2% | $48.01M-24.6% | |
| Tryngolza | $27.1M— | —— | $31.79M+65.0% | $19.27M+207% | $6.29M— | |
| Wainua Joint Development Revenue | $17.62M+83.4% | $9.61M-0.8% | $9.69M-21.7% | $12.37M+18.8% | $10.41M-76.3% | |
| Wainus Royalties | $10.71M-33.0% | $15.98M+20.0% | $13.32M+27.9% | $10.42M+11.1% | $9.37M-5.6% | |
| Percentage Of Royalty Payments Paid On Annual Sales Of Medicine by Product | ||||||
| Pelacarsen | 25%— | —— | 25%0.0pp | 25%0.0pp | 25%— | |
| Spinraza | 45%— | —— | 45%0.0pp | 45%0.0pp | 45%0.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ionis Pharmaceuticals break its business down?
- Ionis Pharmaceuticals (IONS) reports revenue by product across 11 parts — Collaborative Agreement Revenue, Commercial, DAWNZERA Sales, Other Commercial and Other Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Ionis Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ionis Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
